

What is claimed is:

- What is claimed is.

 1. A method of treating a living body having a primary tumor and a metastatic tumor, said method comprising:
 - identifying a primary tumor tissue site of the living body;
 - combining an administration of an immunologic adjuvant at a predetermined concentration to said body, said predetermined concentration being approximately a standard concentration for immunization procedures of said body, said administered immunologic adjuvant resulting in a systemic condition of heightened nonspecific enhanced immune system of the body, including an increased level of nonspecific immune-related molecular and cellular factors and cells, and an administration of a photodynamic light therapy proximate said primary tumor tissue site, said photodynamic light therapy having a light wavelength and a sufficient light dosage to eradicate tumor cells within the primary tumor tissue site, said eradicated primary tumor tissue site cells releasing necrosis-related tumor cell specific antigens; and
 - promoting and enhancing a systemic immunologic response of said body as a result of an interaction between the increased level of nonspecific immune-related molecular and cellular factors and cells and photodynamic light therapy released tumor cell specific antigens, said systemic immunologic response yielding increased levels of tumor cell specific antibodies and other immunologic anti-tumor cell specific products and cells for eradicating cells of the metastatic tumor.
 2. The method of claim 1 wherein the light wavelength ranges from about 400 nm to about 800 nm, the light dosage ranges from about 10 J/cm² to about 250 J/cm² and a light dosage rate ranges from about 50 mw/cm² to about 200 mw/cm².
 3. The method of claim 1 wherein the wavelength ranges from about 300 nm to about 700 nm.
 4. The method of claim 1 wherein the administration of the immunologic adjuvant is achieved via one or more of the group containing an intravenous injection,

an injection proximate the primary tumor site, a topical administration, a subcutaneous injection, and an injection within the primary tumor site.

5. The method of claim 1 wherein the step of administering the photodynamic light therapy includes the step of administering a photosensitizing agent.

6. The method of claim 5 wherein the administration of the photosensitizing agent is achieved via one or more of the group containing an intravenous injection, an injection proximate the primary tumor site, a topical administration, a subcutaneous injection, and an injection within the primary tumor site.

7. The method of claim 1 wherein the immunologic adjuvant is DETOX.

8. The method of claim 7 wherein the DETOX is administered at a 10% full strength concentration.

9. The method of claim 1 wherein the administration of the immunologic adjuvant precedes the administration of the photodynamic light therapy.

10. The method of claim 1 wherein the administration of the photodynamic light therapy precedes the administration of the immunologic adjuvant.

11. The method of claim 1 wherein the administration of the photodynamic light therapy and the administration of the immunologic adjuvant occur at least in part simultaneously.

12. The method of claim 1 wherein the administration of the immunologic adjuvant includes one or more separate administrations of the adjuvant to the body.

13. The method of claim 1 wherein the administration of the immunologic adjuvant includes administrations before and after the administration of the photodynamic light therapy.

- Sub A3*
- D*
- DO NOT EXPOSE TO SUNLIGHT*
14. The method of claim 1 further comprising the step of:
administering of an immune modulator to the body before, during, or after
the administration of photodynamic light therapy.
15. The method of claim 14 wherein the immune modulator is administered at
multiple times to the body.
16. A method of eradicating acellular organisms of a living body by promoting a
systemic immunologic activity, said method comprising the steps of:
identifying an acellular organism site of the living body;
combining an administration of an immunologic adjuvant to said body, said
immunologic adjuvant promoting a systemic increased level of molecular and cellular
factors and cells necessary to effect a systemic immunologic response and an
administration of a photodynamic light therapy proximate said acellular organism site,
said photodynamic light therapy having a sufficient light dosage to cause cell necrosis
of an acellular organism within the acellular organism site, said photodynamic acellular
organism necrosis resulting in the release of necrosis-generated acellular organism
antigens; and
promoting and enhancing a systemic acellular organism-related immunologic
response of said body as a result of an interaction between the molecular and cellular
factors and cells and the necrosis-generated acellular organism specific antigens, said
systemic immunologic response yielding an increased level of acellular organism
specific antibodies and other immunologic acellular organism specific products and
cells specifically targeted to immunologically eradicate similar acellular organisms.
17. The method of claim 16 wherein the administration of the immunologic
adjuvant precedes the administration of the photodynamic light therapy.
18. The method of claim 16 wherein the administration of the photodynamic
light therapy precedes the administration of the immunologic adjuvant.

19. The method of claim 16 wherein the administration of the photodynamic light therapy and the administration of the immunologic adjuvant occur at least in part simultaneously.

20. The method of claim 16 wherein the light wavelength ranges from about 400 nm to about 800 nm, the light dosage ranges from about 10 J/cm² to about 250 J/cm² and a light dosage rate ranges from about 50 mw/cm² to about 200 mw/cm².

21. The method of claim 16 wherein the wavelength ranges from about 300 nm to about 700 nm.

22. The method of claim 16 wherein the administration of the immunologic adjuvant is achieved via one or more of the group containing an intravenous injection, an injection proximate the acellular organism site, a topical administration, a subcutaneous injection, and an injection within the acellular organism site.

23. The method of claim 16 wherein the step of administering the photodynamic light therapy includes the step of administering a photosensitizing agent.

24. The method of claim 16 wherein the administration of the photosensitizing agent is achieved via one or more of the group containing an intravenous injection, an injection proximate the acellular organism site, a topical administration, a subcutaneous injection, and an injection within the acellular organism site.

25. The method of claim 16 wherein the immunologic adjuvant is DETOX.

26. The method of claim 16 further comprising the step of:
administering the immunologic adjuvant to the body for a period of time
following the photodynamic light therapy.

27. The method of claim 16 further comprising the step of:
repeating the administrations of the photodynamic light therapy.

28. The method of claim 16 further comprising the step of:
repeating the administrations of the immunologic adjuvant.
29. The method of claim 16 wherein the acellular organism is a fungus.
30. The method of claim 16 wherein the acellular organism is a virus.
31. The method of claim 16 further comprising the step of:
administering of an immune modulator to the body before, during, or after
the administration of photodynamic light therapy.
32. The method of claim 31 wherein the immune modulator is administered to
the body at more than one administration.
33. A method of eradicating cellular organisms of a living body by promoting a
systemic immunologic activity, said method comprising the steps of:
identifying a cellular organism site of the living body;
combining an administration of an immunologic adjuvant to said body, said
immunologic adjuvant promoting a systemic increased level of molecular and cellular
factors and cells necessary to effect a systemic immunologic response and an
administration of a photodynamic light therapy proximate said cellular organism site,
said photodynamic light therapy having a sufficient light dosage to cause cell necrosis
of a cellular organism within the cellular organism site, said photodynamic cellular
organism necrosis resulting in the release of necrosis-generated cellular organism
antigens; and
promoting and enhancing a systemic cellular organism-related immunologic
response of said body as a result of an interaction between the molecular and cellular
factors and cells and the necrosis-generated cellular organism specific antigens, said
systemic immunologic response yielding an increased level of cellular organism specific
antibodies and other immunologic cellular organism specific products and cells
specifically targeted to immunologically eradicate similar cellular organisms.

34. The method of claim 33, wherein the administration of the immunologic adjuvant precedes the administration of the photodynamic light therapy.

35. The method of claim 33, wherein the administration of the photodynamic light therapy precedes the administration of the immunologic adjuvant.

36. The method of claim 33, wherein the administration of the photodynamic light therapy and the administration of the immunologic adjuvant occur at least in part simultaneously.

37. The method of claim 33 wherein the administration of the immunologic adjuvant is achieved via one or more of the group containing an intravenous injection, an injection proximate the cellular organism site, a topical administration, a subcutaneous injection, and an injection within the cellular organism site.

38. The method of claim 33 wherein the administration of the photosensitizing agent is achieved via one or more of the group containing an intravenous injection, an injection proximate the cellular organism site, a topical administration, a subcutaneous injection, and an injection within the cellular organism site.

39. The method of claim 33 further comprising the step of:
administering the immunologic adjuvant to the body for a period of time following the photodynamic light therapy.

40. The method of claim 33 further comprising the step of:
repeating the administrations of the photodynamic light therapy.

41. The method of claim 33 further comprising the step of:
repeating the administrations of the immunologic adjuvant.

42. The method of claim 33 wherein the cellular organism is a bacteria or a parasite.

- D
43. The method of claim 33 further comprising the step of:
administering of an immune modulator to the body before, during, or after
the administration of photodynamic light therapy.
44. The method of claim 43 wherein the immune modulator is administered to
the body at more than one administration.

ADD
ATT

TELETYPE REC'D 02/22/90